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Summary
Polyphosphate (polyP) binds to fibrin(ogen) and alters fibrin structure, 
generating a heterogeneous network composed of ‘knots’ inter-
spersed by large pores. Here we show platelet-derived polyP elicits 
similar structural changes in fibrin and examine the mechanism by 
which polyP alters fibrin structure. Polymerisation of fibrinogen with 
thrombin and CaCl2 was studied using spinning disk confocal (SDC) 
microscopy. PolyP delayed fibrin polymerisation generating shorter 
protofibrils emanating from a nucleus-type structure. Consistent with 
this, cascade blue-polyP accumulated in fibrin ‘knots’. Protofibril 
formation was visualized by atomic force microscopy (AFM) ± polyP. In 
the presence of polyP abundant monomers of longer length were vis-
ualised by AFM, suggesting that polyP binds to monomeric fibrin. 
Shorter oligomers form in the presence of polyP, consistent with the 
stunted protofibrils visualised by SDC microscopy. We examined 
whether these structural changes induced by polyP alter fibrin’s vis-
coelastic properties by rheometry. PolyP reduced the stiffness (G’) and 
ability of the fibrin network to deform plastically G’’, but to different 
extents. Consequently, the relative plastic component (loss tangent 
(G’’/G’)) was 61 % higher implying that networks containing polyP are 
less stiff and more plastic. Local rheological measurements, performed 
using magnetic tweezers, indicate that the fibrin dense knots are 
stiffer and more plastic, reflecting the heterogeneity of the network. 
Our data show that polyP impedes fibrin polymerisation, stunting 
protofibril growth producing ‘knotted’ regions, which are rich in fibrin 
and polyP. Consequently, the mechanical properties of the fibrin net-
work are altered resulting in clots with overall reduced stiffness and 
increased ability to deform plastically.
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Coagulation and Fibrinolysis
Introduction
Abnormal clot structure is linked to a number of thrombotic dis-
eases (1–5). The composition of the fibrin network determines the 
mechanical properties and its stability. Fibrinogen levels are di-
rectly associated with fibrin clot structure, with higher concen-
trations leading to an increase in the number and length of the 
fibres as well as enhancing fibre diameter. In line with these obser-
vations elevated levels of plasma fibrinogen are a risk factor for 
cardiovascular disease (6). Thrombin concentration has a pro-
found impact on the architecture of a fibrin clot, (7) with high con-
centrations producing clots composed of thin compactly packed 
fibres. It is these dense clots that are linked to venous and arterial 
thromboembolic complications (2, 3, 5, 8–10). The resulting struc-
ture of a clot dictates the rate of fibrinolysis. Individually, thin 
fibres are lysed quicker however, at the network level, clots 
composed of thick loosely woven fibres are lysed more rapidly 
(11). Therefore, it is the composition of the fibrin network that in-
fluences clot resolution rather than individual fibre diameter.
PolyP is a biomolecule composed of orthophosphate residues 
(Pi) linked by phosphoanhydride bonds. PolyP of an average chain 
length of 60–100 mers is released from the dense granules of stimu-
lated platelets (12, 13). Activation of normal circulating levels of 
platelets is sufficient to generate concentrations of around 1–3 µM 
polyP in whole blood (12, 14). However, in the milieu of a throm-
bus local polyP concentrations are likely to be several orders of 
magnitude higher due to the substantial accumulation of platelets. 
PolyP is both pro-inflammatory and pro-coagulant in vivo (13, 15) 
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and modulates haemostasis at a number of points in the cascade 
(reviewed in (16)) including binding fibrin(ogen) and altering the 
structure of the resulting clot (17, 18). Inhibition of polyP inhibits 
thrombin generation at arterial shear rates and fibrin generation at 
both venous and arterial shear rates (19) and polyP inhibitors have 
been recently proposed as novel antithrombotic agents (20, 21).  
We have shown that fibrin networks produced in the presence of 
polyP are very heterogeneous with dense ‘knotted’ regions inter-
spersed by pores (18). A consequence of this altered structure is at-
tenuation of tissue plasminogen activator (tPA) and plasminogen 
binding to fibrin thereby down-regulating tPA (16)-mediated fibri-
nolysis in the presence of polyP (18). The regulatory role of polyP 
in haemostasis has been proposed to act to promote rapid resol-
ution of injury upon activation of platelets by enhancing coagu-
lation, whilst inhibiting fibrinolysis to allow repair (14).
Here we sought to determine the molecular mechanisms 
underlying the structural changes observed in fibrin clots formed 
in the presence of polyP of approximately the size range of that 
found in platelets (60–100 mer) (13). We investigated changes in 
early fibrin polymerisation in the presence of polyP in real-time 
using spinning disk confocal (SDC) microscopy and at high resol-
ution using atomic force microscopy. PolyP delayed fibrin poly-
merisation producing stunted protofibrils which moved with a re-
duced velocity. Rheological measurements indicate that clots 
formed with polyP exhibit altered mechanical properties which 
may alter their ability to respond to shear stress in vivo.
Materials and methods
Materials
Plasminogen free human fibrinogen (Fib 1) and Glu-plasminogen 
were purchased from Enzyme Research Laboratories (Swansea, 
UK). Alexa-fluor 488 (AF488) conjugated fibrinogen from human 
plasma, Cascade Blue™ ethylenediamine, trisodium salt were from 
Molecular Probes (Leiden, The Netherlands) and 4.5 µm super-
paramagnetic beads (Dynabeads M-450 Epoxy) were from Life 
Technologies (Paisley, UK). Thrombin from human plasma 
(T1063) and polyphosphate (type 65; polyP) were purchased from 
Sigma-Aldrich (Dorset, UK). Capillary tubes for magnetic 
tweezers were 0.5 mm in diameter and 5 cm in length (VitroCom; 
Mountain Lakes, NJ, USA). 1-ethyl-3-[3-(dimethylamino)pro-
pyl]carbodiimide (EDAC), Slide-A-Lyzer dialysis cassettes G2 (2K 
MWCO 3 ml) and DyLight 550™ (DL-550) antibody labelling kit 
were purchased from Thermo Scientific (Rockford, IL, USA). 
PolyP of an average chain length of 70 phosphate monomers, used 
for the cascade blue labelling, was a kind gift from Dr Thomas Staf-
fel BK Giulini GmbH (Ludwigshafen, Germany). Platelet-derived 
polyP was extracted from outdated apheresis platelets as described 
(22). PolyP concentrations are expressed as monomer concen-
trations throughout (monomer formula NaPO3). Where indicated, 
thrombin and fibrinogen concentrations were altered due to the 
specific requirements and constraints of the experimental pro-
cedures. Unless otherwise stated all reactions were carried out with 
human plasminogen-free fibrinogen (1.5 mg/ml) ± polyP (328 
µM) with thrombin (0.25 U/ml) and calcium chloride (5 mM) in 
TBS (50 mM tris, 100 mM NaCl pH 7.4).
Fibrin polymerisation measurements
Changes in turbidity were monitored by taking measurements 
every 30 s at 340 nm for 60 minutes (min) at 37˚C using a BioTek 
ELX808 microplate plate reader. SDC microscopy studies of fibrin 
polymerisation were carried out as previously described (23) with 
the following modifications. Fibrinogen (1.62 mg/ml, 7 % as 
AF488-fibrinogen) was polymerised by the addition of thrombin 
(0.25 U/ml) and CaCl2 (5 mM) ± polyP. Polymerisation reactions 
took place in Ibidi µ slides VI0.4 (Ibidi, Martiensried, Germany) 
with a channel height of 400 µm. A stack of 30 images was ac-
quired every 15 seconds (s) for 45 min at 37˚C on a UltraVIEW 
Vox 3D live cell imaging system with a plan Apo VC ×60/1.40 NA 
oil objective OFN 25 DIC N2 using Velocity software (Perkin 
Elmer, Waltham, MA, USA). The velocity of the moving fibrin 
structures was calculated by measuring the distance travelled be-
tween subsequent images of 3 representative structures from each 
data set using Image J software (National Institutes of Health, Be-
thesda, MD, US).
Clot rheometry
The viscoelastic properties of the overall fibrin network were 
measured on an AR G2 Rheometer (TA Instruments; New Castle, 
DE, USA). Measurements were taken during polymerisation at 37˚C 
every 18 s for 80 min using a 40 mm parallel plate, gap of 220 mm, 
strain of 2 % and frequency of 5 rad/s. The elastic modulus, G’, gives 
information about the energy stored during deformation translated 
into clot stiffness. The loss modulus, G’’, gives information about 
energy loss during deformation translated into the viscous compo-
nent of the clot. The loss tangent tanδ = G”/G’ was also calculated.
In addition, an in-house built magnetic tweezers system was 
used to examine local microrheology in fibrin clots (24) by apply-
ing a magnetic force over a 4.5 µm superparamagnetic bead and 
measuring its displacement in the clot. Clots, formed in the pres-
ence of superparamagnetic beads by addition of thrombin (0.25 
U/ml) to fibrinogen (0.5 mg/ml) and CaCl2 (2.5 mM), ± polyP, 
were immediately transferred to a thin capillary tube and allowed 
to polymerise for 3 hours (h). An electromagnetic force (40 pN) 
was applied using four electromagnets mounted on top of an in-
verted Olympus IX-71 microscope (Olympus; Southend, UK) and 
connected to Kepco BOP 20–5M amplifiers (Kpeco Inc.; Flushing, 
NY, USA) controlled using LabView software (National Instru-
ments; Newbury, UK). The position of the magnetic beads was 
tracked using CCD camera and measurements made, avoiding 
capillary walls where the clot was not densely packed. Both elastic 
and viscous modulus of the fibrin clots were calculated from the 
time-dependent compliance in order to get frequency dependent 
moduli (25). The compliance was calculated as the ratio of the 
time-dependent shear strain (time-dependent bead displacement) 
to the magnitude of the constant stress (force applied). In each clot 
the displacement of 10 particles (in different areas of the clot) were 
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measured and each clot was studied in triplicate. The values pres-
ented in this paper were obtained at 0.1 Hz.
Confocal microscopy
Cascade blue ethylenediamine (CB)-labelled polyP was prepared 
as described (26) and used to visualise its localisation within the fi-
brin network. Briefly, polyP (1 mg/ml) was incubated overnight at 
37˚C with Cascade Blue ethylenediamine (1 mM), CaCl2 (1 mM), 
EDAC (100 mM), and 2-(N-morpholino)ethanesulfonic acid (100 
mM), pH 6.5. CB-polyP adducts were purified using Slide-A-Lyzer 
dialysis cassettes. Clots were formed ± CB-polyP (328 µM) or pla-
telet-derived polyP by polymerising fibrinogen (0.87 mg/ml, con-
taining 9 % labelled with DL550-fibrinogen or AF488-fibrinogen) 
with thrombin (0.25 U/ml) and CaCl2 (5 mM).
To visualise the localisation of the superparamagnetic beads, 
clots were prepared as for the magnetic tweezers microrheology 
experiments in µ-slide VI0.4 (Ibidi) with the inclusion of AF488-
 fibrinogen (0.12 mg/ml). Z-stack images (0.45 or 0.5 µm slices) 
were taken on a Zeiss 710 laser scanning confocal microscope with 
a 63 × 1.40 oil immersion objective using Zeiss Zen 2012 software.
Atomic force microscopy
Protofibril formation was visualised by atomic force microscopy 
(AFM) by clotting fibrinogen (0.5 mg/ml) with thrombin (1 U/ml) 
and CaCl2 ± polyP. Polymerisation was allowed to proceed for 40 s 
before stopping the reaction by diluting in TBS and placing an ali-
quot on freshly cleaved MgCl2 mica pre-treated surface for imaging 
in air using a Bruker Multimode AFM and SNL-A Scanasyst probe.
Statistical analysis
Statistical analysis was performed in GraphPad Prism® 5.04 using 
one-way analysis of variance or two-way analysis of variance with 
Bonferroni post-hoc test or an unpaired Student’s t-test (2-tailed). 
P < 0.05 was considered to be significant. Changes in rates of vel-
ocity (µm2/s) for fibrin polymerisation measured by SDC micro-
scopy were determined by best fit to a centered sixth order polyno-
mial quadratic in GraphPad Prism® 5.04 and used to calculate fold 
differences in velocity.
Results
PolyP accumulates in fibrin dense ‘knots’
The localisation of CB-polyP within the clot was determined using 
confocal microscopy. CB-polyP accumulated in the knotted fibrin 
dense regions with a reduced fluorescent signal detected along the 
fibrin fibres that emanate from the ‘knots’ (▶ Figure 1 A, see also 
Suppl. Video I, available online at www.thrombosis-online.com). 
A control clot formed in the absence of CB-polyP is shown for 
comparison (▶ Figure 1 B). PolyP exists in various polymer 
lengths, with platelet-derived polyP ranging between 60 and 100 
phosphate residues (12, 13). Inclusion of polyP extracted from 
human platelets during fibrin polymerisation mirrored the struc-
tural changes observed with synthetic polyP, with fibrin dense 
knots interspersed by large pores (▶ Figure 1 C).
PolyP alters fibrin polymerisation
Our previous observations showed that polyP reduced the maxi-
mum turbidity of polyP-containing clots indicating an altered fibrin 
network, which we confirmed by confocal and scanning electron 
microscopy (18). There was no detectable change in the lag time, 
however, change in turbidity is a crude measurement which does not 
allow for the real time study of the very early polymerisation events. 
Here we use SDC microscopy to visualise the dynamic process oc-
curring during the first few minutes of polymerisation. Initially, in 
control clots, small very fast moving structures were observed that 
gradually form thicker protofibrils before stabilizing into a fibrin net-
work (Suppl. Video II, available online at www.thrombosis-online.
com). The presence of polyP resulted in smaller structures and de-
layed the time at which the first fibres were first observed by 21 s (p 
<0.05) (▶ Figure 2 A, B). Measurements of velocity were taken by 
tracking the movement of the same structure over time (▶ Figure 
2 C). Quantification of the velocity of the fibrin structures revealed a 
decrease in movement over time in both control and polyP clots 
Figure 1: Visualisation of polyP with fibrin network. Clots were formed 
± CB-polyP or platelet-derived polyP (328 µM) by polymerising fibrinogen 
(0.87 mg/ml, with 9 % labelled with DL550-fibrinogen or AF488-fibrinogen) 
with thrombin (0.25 U/ml) and CaCl2 (5 mM). A) Render of Z-stack represen-
tative image polyP-containing clot with fibrinogen (green, top right panel) 
and polyP (blue, bottom right panel) and the merged image (left panel). 
 Arrows indicate the presence of polyP in fibrin dense regions. B) Control clot 
formed in the absence of polyP. C) Clot containing platelet-derived polyP 
(left) and control clot (right) for comparison. Images were collected using a 
LSM 710 confocal microscope. Representative image from n = 3, scale bar = 
10 µm.
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Figure 3: Protofibril formation visualised using AFM. Fibrinogen (0.5 
mg/ml) was polymerised for 40 s by addition of thrombin (1 U/ml) and CaCl2 
(5 mM) ± polyP and the reaction stopped by diluting. Samples were imaged 
using a Bruker Multimode AFM and SNL-A Scanasyst probe (air). A) Repre-
sentative images of a monomer, dimer, trimer and tetramer structure. Clearly 
distinguishable are the central E regions, D regions and in the monomers the 
αC regions. B) Representative images from control and polyP containing 
reactions. Images show a 1 µm2 area. C) Calculation of structure length using 
 Nanoscope analysis software. Twelve fibrin structures representing 
monomers, dimers, trimers and tetramers were measured from three separ-
ate images.
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(▶ Figure 2 D). This  reduction in velocity over time is likely at-
tributed to the increased size of the structures, due to elongation and 
lateral aggregation of fibres with time (23). Clots containing polyP 
demonstrated a 2.4-fold (p <0.05) reduction in velocity compared to 
control clots (▶ Figure 2 C, D). Stabilised clots (▶ Figure 2 A, right 
panel) polymerised in the presence of polyP displayed the same het-
erogeneous knotted structures as previously observed (▶ Figure 1; 
Suppl. Video I, available online at www.thrombosis-online.com).
Protofibrils are stunted during polymerisation with 
polyP
SDC microscopy is capable of detecting protofibrils of a length of 
0.5 µm and greater (23). We further addressed the effects of polyP 
on early protofibril formation using AFM, which is a very high res-
olution technique that allows detection in the nanometer range. 
▶ Figure 3 A shows representative images of monomers, dimers, 
trimers and tetramers. The structure of the fibrin monomers in-
cluding the αC regions were clearly visible at this high resolution 
(▶ Figure 3 A). After 40 s of polymerisation in the presence of 
polyP more abundant fibrin monomers are observed (▶ Figure 
3 B), indicative of slower fibrin polymerisation, consistent with the 
observations using SDC microscopy. The monomeric fibrin struc-
tures (exhibiting clearly visible D-E-D regions) were approxi-
mately 8.8 nm longer in the presence of polyP compared to the 
control (58.4 ± 1.4 nm vs 49.6 ± 0.6 nm, p <0.0001) (▶ Figure 3 C). 
This elongation likely indicates direct binding of polyP to fibrin 
monomers, consistent with our previous demonstration of interac-
tion with soluble fibrin (18). Binding of polyP to fibrin monomers 
subsequently attenuated the size of the resulting dimers and 
trimers (▶ Figure 3 C). Larger fibrin structures are visible in the 
control clot compared to the polyP containing clot indicative of 
more advanced protofibril formation. These AFM observations 
suggest that the association of polyP and fibrin mechanically alters 
oligomer formation during early fibrin polymerisation steps.
PolyP modulates the rheological properties of the 
clot
We next addressed whether the structural changes in fibrin observed 
in the presence of polyP alter the rheological properties of the clot. 
This was first measured in a rheometer during the polymerisation 
process. Clots containing polyP were 4-fold less stiff than control 
Figure 2: PolyP alters fibrin polymerisation. Fibrinogen (1.62 mg/ml, 
7 % as AF488-fibrinogen) was polymerised by the addition of thrombin (0.25 
U/ml) and CaCl2 (5 mM) ± polyP (328 µM) and monitored by SDC micro-
scopy. A stack of 30 images was acquired every 15 s for 45 min at 37˚C. A) 
Time course images showing delayed polymerisation in the presence of polyP 
and the stabilised clots at 45 min. B) The time at which fibres were first vis-
ualised. C) Overlaid images from representative structures ± polyP at three 
different time points. Arrows indicated direction of movement, scale bar = 10 
µm. D) The velocity of the fibrin structures was calculated by measuring the 
distance travelled between subsequent images of three representative struc-
tures from each data set using Image J software. Data are expressed as mean 
± SEM, n = 4.
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by natural form of polyP isolated from human platelets. Using 
AFM we visualise the association of polyP with fibrin monomers, 
illustrated by the longer length of these microstructures. This 
binding results in accumulation of polyP within fibrin dense re-
gions, suggesting it acts as a nucleus for fibrin formation. In bacte-
ria, polyP functions as a chaperone to stabilise cytoplasmic pro-
teins by binding to unfolded proteins and preventing the 
formation of protein aggregates (27).
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clots (8.3 ± 0.8 Pa vs 34.7 ± 6.9 Pa, p < 0.05) as indicated by their re-
duced storage modulus (G’), which is a measure of the stored energy 
and represents the elastic component (▶ Figure 4 A, B). The loss mo-
dulus (G’’), which represents the energy dissipated as heat, was 2-fold 
higher in the control clots compared to those containing polyP (1.6 ± 
0.1 vs. 0.7 ± 0.01, p < 0.01; ▶ Figure 4 A, B). As the change in the stor-
age modulus was greater, the loss tangent (G’’/G’) for polyP contain-
ing clots was 57 % (p < 0.05) higher in the presence of the polyP, indi-
cating an increase in the relative plastic component (▶ Figure 4 C). 
The lag time was prolonged in clots containing polyP, consistent with 
the delayed polymerisation observed by SDC microscopy. These re-
sults imply that in the presence of polyP the overall fibrin network is 
less stiff and more likely to deform plastically.
The microscale viscoelastic properties of fully polymerised cross-
linked fibrin clots were further investigated using magnetic tweezers. 
In this method clots are polymerised in the presence of suprapara-
magnetic beads which are trapped within the fibrin network. Due to 
the heterogeneous nature of polyP-containing clots, we analysed the 
location of the beads by confocal microscopy and found them to lo-
calise within the knotted fibrin regions (▶ Figure 5 A). The tightly 
knotted fibrin areas in polyP-containing clots were 2-fold stiffer than 
homogeneous control clots (G’ 0.50 ± 0.03 vs 0.23 ± 0.01 Pa, p < 
0.0001) (▶ Figure 5 B). Inclusion of polyP also increased the loss mo-
dulus 2-fold (G’’ 0.24 ± 0.01 vs 0.12 ± 0.01 Pa, p < 0.0001) and as a re-
sult there was no significant difference in the tan delta values. This 
suggests that the fibrin dense knots, which accrue high concen-
trations of polyP, are stiffer in nature. Taken together, these different 
viscoelastic measurements reflect the highly heterogeneous nature of 
the fibrin network formed in the presence of polyP.
Discussion
Our observations (18) and others (17) have previously illustrated 
that polyP modulates the structural properties of a fibrin clot. Here 
we demonstrate that these structural alterations in the fibrin net-
work observed with synthetic polyP are mirrored with natural 
polyP that has been isolated from human platelets. The heteroge-
neity of the fibrin network in the presence of polyP can be at-
tributed to early events during clot development. We visualise fi-
brin formation in real-time using SDC microscopy (23) and show 
that polyP significantly delays polymerisation of fibrin. High res-
olution AFM microscopy reveals binding of polyP to fibrin 
monomers resulting in shorter protofibrils that exhibit reduced 
velocity during polymerisation. These changes in polymerisation 
generate clots composed of fibrin dense aggregates, which contain 
a polyP-rich core, and are interspersed by large porous regions. 
The extremely heterogeneous nature of polyP-containing clots is 
echoed in their viscoelastic properties, with distinct differences in 
the microscale and overall clot stiffness.
PolyP binds to fibrinogen and soluble fibrin (18) and is incor-
porated into clots during polymerisation (17). PolyP stored in pla-
telet dense granules has a defined chain length of 60–10 phosphate 
residues (12, 13) Here, we demonstrate that the structural changes 
observed with synthetic polyP are representative of those induced 
Figure 4: Rheological properties of the fibrin network. Measurements 
were taken during polymerisation of fibrinogen (1.5 mg/ml) ± polyP (328 
µM) by the addition of thrombin (0.25 U/ml) and CaCl2 (5 mM) on a rheo-
meter at 37˚C every 18 s for 80 min. Shown are plots (A) and histograms (B) 
of the average storage (G’) and loss (G’’) moduli and (C) the loss tangent 
([Formula: tanδ=G‘‘G‘]). * P <0.05, ** P <0.01 compared with control clots. 
Data are expressed as mean ± SEM, n = 3.
Figure 5: Magnetic tweezers measurements of the local rheological 
properties. Fibrin clots were formed by addition of thrombin (0.25 U/ml) to 
fibrinogen (0.5 mg/ml) and CaCl2 (2.5 mM), ± polyP (328 µM) in the presence 
of superparamagnetic beads. A) Localisation of the superparamagnetic beads 
was visualized within the clots with the inclusion of AF488-fibrinogen (19 % 
of total fibrinogen) on a Zeiss 710 laser scanning confocal microscope. DIC = 
differential interference contrast. Arrows indicate supraparamagnetic beads, 
scale bar = 10 µm. B) An electromagnetic force (40 pN) was applied and the 
position of the magnetic beads tracked using CCD camera. Displacement of 
10 particles per clot were measured and each clot was studied in triplicate. 
The values presented were obtained at frequency 0.1Hz. **** P <0.0001, 
compared with control clots. Data are expressed as mean ± SEM, n = 3.
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Precipitation of polyP into spherical nanoparticles in the pres-
ence of 5 mM CaCl2 has recently been described (28). These nano-
particles had more potent activity towards the contact system. We 
have previously shown that polyP has the most pronounced effect 
on fibrinolysis at a CaCl2 concentration of 2.5–5 mM (18) and in 
these studies have used 5 mM throughout. We also found that the 
polyP used in this study was visualised as a spherical form by AFM 
(data not shown), suggesting it functions as a polyP nanoparticle. 
During fibrin polymerisation polyP may act as a surface that at-
tracts fibrinogen, creating dense areas of fibrin. This initial net-
work forms the scaffold for deposition of subsequent fibrinogen 
molecules (29, 30). Therefore the localisation of polyP within these 
early stages of polymerisation may act as a blueprint for the result-
ing fibrin network.
The rate of polymerisation has a direct impact on the resulting 
fibrin network structure. During the lag phase there is rapid move-
ment of fibrin structures with formation of the initial scaffold cor-
responding to the gel point (30). As the turbidity increases the 
scaffold stabilises allowing branch point formation and lateral 
growth of fibres (30). In general, the turbidity of fibrin gels is pro-
portional to the average cross-sectional area of the fibres (31). 
However, in the presence of polyP, the resulting heterogeneous clot 
structure provides an example of a clot where the turbidity is not 
proportional to the average cross-sectional area of the fibres. Inclu-
sion of polyP delayed polymerisation observed by SDC micro-
scopy producing stunted fibrin structures with reduced mobility. 
Consistent with the SDC microscopy, AFM revealed a reduction in 
oligomer length, which is directly linked to the rate of polymeri-
sation (32).
The viscoelastic properties of the fibrin network are closely re-
lated to its mechanical stability. Here the rheological properties of 
polyP-containing clots, quantified during polymerisation, demon-
strated a reduction in both the storage and loss moduli. The de-
crease in storage modulus was greater, resulting in an increased 
loss tangent indicating that polyP-containing clots are less stiff 
with an increased plastic component. These characteristics may 
seem conflicting; however, they likely reflect the heterogeneous 
nature of these clots, with the porous loose regions accounting for 
the reduction in stiffness. We also assessed the local rheological 
properties of fully polymerised and cross-linked clots using mag-
netic tweezers. In these measurements the supraparamagnetic 
beads were directly incorporated into the knotted regions of fibrin 
that are rich in polyP. Using this technique we found an increase in 
the storage modulus with polyP, indicative of an increased stiff-
ness. These observations are in agreement with thromboelas-
tography measurements performed on fully polymerised clots 
(17). These differences, while conflicting reflect the ongoing 
changes that occur in a fibrin network when it transitions from the 
polymerisation stage to a fully formed scaffold (30). The addition, 
removal or inhibition of factor XIII does not alter the effects of 
polyP (17, 18). Therefore, the changes in the fibrin network are not 
explained by differences in cross-linking. Changes in the viscoel-
astic properties of a clot will affect how it responds to forces such 
as blood flow. Clots with a reduced storage modulus are more 
likely to deform irreversibly and as the plastic component of these 
clots increases, induced deformation is likely to be permanent 
(33). The stiffness of the clot remains constant over a range of dif-
ferent rates of stress (33) therefore within platelet-rich areas of a 
clot, with high local concentrations of polyP, this would reduce the 
overall stiffness and modulate how the clot reacts to different 
stresses such as clot retraction and shear rate.
The αC region of fibrinogen compromises the terminal two 
thirds of the carboxyl terminal of the Aα chain. During conversion 
of fibrinogen to fibrin the αC regions dissociate from the central E 
domain allowing intermolecular interactions and enhancing lat-
eral aggregation (34–36). Interestingly, clots formed with fibri-
nogen truncated at Aα residue 251, show a reduction in stiffness 
and more plastic deformation (37). There is a net positive charge 
on the αC regions which could favour interaction with negatively 
charged polymers such as polyP (38). The αC regions are the most 
unfolded part of fibrin(ogen) and in view of the fact that polyP 
acts as chaperone to unfolded proteins in bacteria (27), it is con-
ceivable that it interacts with polyP in a similar manner. PolyP in-
creased the length of fibrin monomers which could be due to the 
αC region extending beyond the D-region, resulting in longer 
structures. During formation of larger structures the αC region has 
to extend laterally rather than longitudinally to allow D-D interac-
tions which could be enhanced by polyP, perhaps resulting in the 
observed shortened oligomers. It is interesting to speculate that by 
binding to this region polyP alters the structural and rheological 
properties of the fibrin network, but further work is necessary to 
characterise the exact binding site of polyP on fibrinogen.
Detection of abnormal changes to clot structure has the poten-
tial as a biomarker of thrombotic disease. Recently, clot fractal di-
mension (df) has been proposed as a test for abnormal clot micro-
structure and predictor of recurrent VTE (39). Changes in the fi-
brin network translate into alterations in the susceptibility to fibri-
nolysis. The resulting heterogeneous network with polyP has a re-
duced permeability and the rate of fibrinolysis by tPA is reduced 
due to impaired binding of tPA and plasminogen to partially de-
graded fibrin (18). Interestingly, the binding sites for tPA and plas-
minogen on fibrin are also concentrated in the αC regions suggest-
ing a possible mechanism by which polyP attenuates binding of 
these proteins.
In conclusion, we have shown that platelet-derived polyP elicits 
the same structural changes in fibrin as previously described for 
synthetic polyP. We found that polyP modulated the early 
What is known about this topic?
• PolyP binds to fibrin(ogen).
• PolyP alters the fibrin network structure forming clots with fibrin 
aggregates interspersed by large pores.
What does this paper add?
• PolyP delays fibrin polymerisation and stunts protofibril growth.
• PolyP is localised in the dense fibrin knots.
• Overall clots containing polyP are less stiff and more likely to 
 deform plastically.
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 polymerisation events of fibrin formation by binding directly to 
 fibrin(ogen), thereby altering oligomer formation, producing 
stunted fibrin structures that move with reduced velocity. PolyP 
acts as a nucleus for dense accumulations of fibrin which are inter-
spersed by a looser porous network. The heterogeneous nature of 
the network is conveyed in its viscoelastic properties producing a 
clot with reduced stiffness and increased ability to deform plasti-
cally, but with local micro-pockets of increased stiffness in areas 
where polyP is concentrated on fibrin.
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